Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 6/20 | 0.74 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.74 |
| ▸ | IKBKB | O14920 | 2/20 | 0.72 |
| ▸ | KDR | P35968 | 3/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.57 |
| ▸ | CDK1 | P06493 | 2/20 | 0.57 |
| ▸ | CDK4 | P11802 | 2/20 | 0.57 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.57 |
| ▸ | CCND1 | P24385 | 2/20 | 0.57 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.57 |
| ▸ | CDK7 | P50613 | 2/20 | 0.57 |
| ▸ | CDK9 | P50750 | 2/20 | 0.57 |
| ▸ | CCNH | P51946 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11296744 | 0.94 | IKBKB (0.73) | CDK2CCNA2IKBKBKDRCYP1A2 | |
| SCHEMBL3520848 | 0.84 | IKBKB (1.00) | CDK2CCNA2IKBKBCYP1A2CYP3A4 | |
| SCHEMBL11299433 | 0.84 | IKBKB (0.71) | CDK2CCNA2IKBKBKDRCYP1A2 | |
| SCHEMBL11296762 | 0.84 | IKBKB (0.71) | CDK2CCNA2IKBKBKDRCYP1A2 | |
| SCHEMBL11299366 | 0.84 | IKBKB (0.71) | CDK2CCNA2IKBKBKDRCYP1A2 | |
| SCHEMBL13439677 | 0.84 | IKBKB (0.71) | CDK2CCNA2IKBKBKDRCYP1A2 | |
| SCHEMBL13439675 | 0.82 | IKBKB (0.61) | CDK2CCNA2IKBKBKDRCYP1A2 | |
| SCHEMBL29929637 | 0.81 | CYP1A2 (0.66) | CDK2CCNA2IKBKBCYP1A2CYP3A4 | |
| SCHEMBL12330249 | 0.81 | CYP1A2 (0.62) | CDK2CCNA2IKBKBCYP1A2CYP3A4 | |
| SCHEMBL4986074 | 0.81 | CYP1A2 (0.66) | CDK2CCNA2IKBKBCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288400-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120183577-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | disclosed |
| US-8017619-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-13 | — | — | US | disclosed |
| US-20100280026-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-04 | — | — | US | disclosed |
| CN-101824043-A | The composition that can be used as kinases inhibitor | VERTEX PHARMA | 2010-09-08 | — | — | CN | disclosed |
| CN-1894258-B | Compositions useful as protein kinase inhibitors | VERTEX PHARMA CO LTD | 2010-06-16 | — | — | CN | disclosed |
| US-7700609-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-20 | — | — | US | disclosed |
| EP-1692140-B1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2009-12-09 | — | — | EP | disclosed |
| CN-1894258-A | Compositions useful as protein kinase inhibitors | VERTEX PHARMA (US) | 2007-01-10 | — | — | CN | disclosed |
| US-20050148603-A1 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280026-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K1, MAP3K6 | CDK2 65/4885CCNA2 725/4885IKBKB 540/4885 |
| US-20050148603-A1 | Compositions useful as inhibitors of protein kinases | MAP3K20, MAP3K1, MAP3K6 | CDK2 65/4885CCNA2 725/4885IKBKB 540/4885 |
| US-20120183577-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K1, MAP3K6 | CDK2 65/4885CCNA2 725/4885IKBKB 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.